Active substanceHydroxymethylquinoxaline dioxideHydroxymethylquinoxaline dioxide
Similar drugsTo uncover
  • Viuxidin®
    concentrate d / infusion 
    TRIVIUM-XXI, LLC     Russia
  • Dixin
    solution c / cavity externally 
    ATOLL, LLC     Russia
  • Dioxydin®
    solution d / infusion externally 
    VALENTA PHARM, PAO     Russia
  • Dioxydin
    solution c / cavity externally 
    BIOSINTEZ, PAO     Russia
  • Dioxydin
    ointment externally 
    BIOSINTEZ, PAO     Russia
  • Dioxydin®
    ointment cutaneous externally 
    NIZHFARM, JSC     Russia
  • Dioxydin
    solution in / in 
  • Imibact®
    solution c / cavity externally 
    SYNTHESIS, OJSC     Russia
  • Imibact®
    solution locally in / in externally 
    SYNTHESIS, OJSC     Russia
  • Imibact®
    ointment locally externally 
    SYNTHESIS, OJSC     Russia
  • Urotravenol
    solution v / vesular 
    MTS MEDICINE, LLC     Russia
  • Dosage form: & nbspRAsterol for intravenous administration, topical and topical application
    Composition:

    Active substance: hydroxymethylquinoxaline dioxide 5.0 mg;

    Excipient: water for injection-up to 1 ml.

    Description:

    Transparent liquid is greenish-yellow in color.

    Note: AT In the case of the precipitation of crystals of hydroxymethylquinoxaline dioxide in ampoules during storage, they are dissolved by heating ampoules in a boiling water bath with shaking until the crystals are completely dissolved (clear solution). If the crystals do not fall again upon cooling to 36-38 ° C, the preparation is usable.

    Pharmacotherapeutic group:Antimicrobial agent - quinoxaline
    ATX: & nbsp

    J.01.X.X   Other antibacterial drugs

    Pharmacodynamics:

    Antibacterial bactericidal preparation of a wide spectrum of action from the group of quinoxaline derivatives.

    Active with respect to:

    - Gram-negative aerobic microorganisms: Esherichia coli, Klebsiella pneumoniae (Friedlander's wand), Proteus vulgaris, Pseudomonas aeruginosa, Salmonella spp., Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei;

    - Gram-positive aerobic microorganisms: Staphylococcus spp., Streptococcus spp .;

    - pathogenic anaerobic microorganisms: Clostridium perfringens.

    It acts on strains of bacteria resistant to other antimicrobial medicines, including antibiotics of different groups. Possible development of drug resistance of bacteria.

    The mechanism of the bactericidal effect of hydroxymethylquinoxaline dioxide is the damage to the biosynthesis of the DNA of a microbial cell, which causes morphological changes in the cell wall and the genetic material of the bacteria.

    At intravenous introduction is characterized by small therapeutic breadth, in this connection strict observance of recommended doses is necessary.

    Treatment of burns and purulent-necrotic wounds promotes faster cleaning of the wound surface, stimulates reparative regeneration and marginal epithelization, and favorablyaffects the course of the wound process.

    Pharmacokinetics:After intravenous administration, the maximum concentration in the blood (CmOh) - 1-2 hours, the therapeutic concentration of the drug in the blood is maintained for 4-6 hours. The drug penetrates well and quickly into all organs and tissues, it is well absorbed from the wound surfaces with local and external application. In the body it is not metabolized. It is excreted by the kidneys. With repeated administration does not accumulate in the body.
    Indications:

    Treatment of various forms of purulent bacterial infection caused by sensitive microflora, with ineffectiveness of other chemotherapeutic agents or their poor tolerability.

    Severe septic conditions (including those with burn disease), purulent meningitis, severe purulent-inflammatory processes with symptoms of infection generalization.

    Wound and burn infection (superficial and deep wounds of various locations, long-term non-healing wounds and trophic ulcers, soft tissue phlegmon, infected burns, purulent wounds in osteomyelitis), pustular skin diseases.

    Contraindications:

    Hypersensitivity to hydroxymethylquinoxaline dioxide, other drugs of the quinoxaline group, adrenal insufficiency (including anamnesis), pregnancy, breast-feeding period, children under 18 years of age.

    Carefully:Renal failure.
    Pregnancy and lactation:

    During pregnancy and during breastfeeding, the drug is contraindicated. In preclinical studies it was shown that hydroxymethylquinoxaline dioxide has a teratogenic and embryotoxic effect, has mutagenic properties.

    The use of the drug during lactation is possible only after the transfer of the child to artificial feeding.

    Dosing and Administration:

    Intravenous administration

    Intravenously drip (at a speed of 60-80 drops per minute) under the supervision of a doctor. Enter a solution of 5 mg / ml, which is previously diluted in a 5% solution of dextrose (glucose) or in a 0.9% solution of sodium chloride to a concentration of 1-2 mg / ml (0.1-0.2%).

    The daily dose the drug is administered once or in 3-4 times during the day (fractional administration). The drug is administered at a rate of 60-80 drops / min for 30 minutes.

    In severe septic conditions the maximum single dose is 300 mg (60 ml of a solution of 5 mg / ml), the daily dose is 600 mg of hydroxymethylquinoxaline dioxide (ie 120 ml of a solution of 5 mg / ml).

    With purulent meningitis daily dose of 600 mg of hydroxymethylquinoxaline dioxide (that is, 120 ml of a solution of 5 mg / ml).

    In chronic purulent processes in the lungs in the stage of exacerbation with signs of generalization daily dose of 500-600 mg of hydroxymethylquinoxaline dioxide (that is, 100-120 ml of a solution of 5 mg / ml).

    When treating a severe purulent urinary tract infectionth day dose - 200-400 mg of hydroxymethylquinoxaline dioxide (ie 40-80 ml of a solution of 5 mg / ml).

    For patients with impaired renal function the dose of the drug is reduced by 2 times.

    In elderly patients it may be necessary to reduce the dose in the event of a violation of kidney function.

    In the case of precipitation of crystals of hydroxymethylquinoxaline dioxide, the crystals are dissolved in ampoules with a solution, heating ampoules in a boiling water bath with shaking until the crystals dissolve completely (the solution should become transparent). If the crystals do not drop again when the ampoules with the drug are cooled to 36-38 ° C, the preparation is suitable for use.

    Local and external use

    Apply 1-5 mg / ml solutions of hydroxymethylquinoxaline dioxide. To obtain a solution of the desired concentration, the drug is diluted with a sterile 0.9% solution of sodium chloride or water for injection.

    For the treatment of superficial purulent wounds on the wound surface, previously cleaned from purulent-necrotic masses, apply napkins moistened with a solution of the drug. Bandages are changed daily or every other day, depending on the condition of the wound or the course of the wound process.

    Deep Wounds after treatment loosely tamponized with tampons moistened with the drug solution. Dressings are done once a day.

    The maximum daily dose of hydroxymethylquinoxaline dioxide is 2.5 g (500 ml of a solution of 5 mg / ml). Duration of treatment - up to 3 weeks.

    For the treatment of deep purulent wounds in osteomyelitis (wounds of the hand, feet) apply a solution of the drug in the form of trays or special treatment of the wound with the drug for 15-20 minutes (insertion of the solution into the wound at this time), followed by the application of dressings moistened with a solution.

    For long-term washing of wounds Apply a solution of hydroxymethylquinoxaline dioxide 1 mg / ml (draining the wound with a thin catheter, rinsing with a few drops for 3-4 hours 1-2 times a day, but not more than 400-500 ml of solution for rinsing).

    To prevent infections after surgery 1-2 mg / ml solutions of the drug are used.

    According to the indications (patients with osteomyelitis) and with good tolerability, treatment can be carried out daily for 1.5-2 months.

    In the case of precipitation of crystals of hydroxymethylquinoxaline dioxide, the crystals are dissolved in ampoules with a solution, heating ampoules in a boiling water bath with shaking until the crystals dissolve completely (the solution should become transparent). If the crystals do not drop again when the ampoules with the drug are cooled to 36-38 ° C, the preparation is suitable for use.

    Side effects:

    With intravenous administration headache, chills, fever, dyspepsia (nausea, vomiting, diarrhea), muscle cramps, allergic reactions (rash, urticaria), photosensitizing effect (the appearance of pigmented spots on the body when exposed to sunlight).

    With external application - itching, dermatitis.

    Overdose:

    When an overdose of the drug may develop acute adrenal insufficiency, which requires the immediate withdrawal of the drug and appropriate replacement therapy.

    Interaction:

    There is no information on the interaction of the drug with other drugs.

    Special instructions:

    The drug is used under strict medical supervision in a hospital.

    Intravenous intravenous injection is unacceptable!

    It is prescribed only for severe forms of infectious diseases or for ineffectiveness of other antibacterial drugs, including cephalosporins II-IV generation, fluoroquinolones, carbapenems.

    Hydroxymethylquinoxaline dioxide is characterized by a narrow therapeutic latitude (strict control over compliance with recommended doses is necessary), therefore it is necessary to strictly follow the recommended doses and not to allow their excess.

    To prevent adverse reactions, it is recommended to use in combination with antihistamines and calcium preparations.

    If adverse reactions occur, reduce the dose, prescribe antihistamines, and if necessary, cancel the drug.

    With renal failure, the dose is reduced.

    When used in elderly people, the age-related decrease in renal function should be considered, which may require a reduction in the dose of the drug.

    When pigmented spots appear with intravenous administration, the duration of administration of a single dose is increased to 1.5-2 hours, the dose is reduced, antihistamines are prescribed or the drug is canceled.

    The precipitation of crystals of hydroxymethylquinoxaline dioxide in ampoules during the storage is allowed. In the case of the precipitation of crystals of hydroxymethylquinoxaline dioxide, they are dissolved by heating the ampoules in a boiling water bath with shaking until the crystals are completely dissolved (clear solution). If the crystals do not fall again upon cooling to 36-38 ° C, the preparation is usable.

    Effect on the ability to drive transp. cf. and fur:

    During the treatment period, care should be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased attention and speed of psychomotor reactions.

    Form release / dosage:

    Solution for intravenous administration, topical and topical application, 5 mg / ml.

    Packaging:

    For 5 or 10 ml in ampoules of colorless or light-protective neutral glass.

    10 ampoules in boxes of cardboard.

    For 5 ampoules of 5 ml or 10 ml in contiguous cells from a polyvinyl chloride film and foilaluminum printed lacquered or without foil.

    1 or 2 contour squares per 5 ampoules in a pack of cardboard.

    Each instruction pack or box is supplied with instructions for use, the ampoule scaler.

    When using ampoules with a kink ring or with a notch and a dot the ampoule scaper is not inserted.

    Storage conditions:

    In the dark place at a temperature of 18 ° C to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-003621
    Date of registration:12.05.2016
    Expiration Date:12.05.2021
    The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspSYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products SYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products Russia
    Information update date: & nbsp24.10.2017
    Illustrated instructions
      Instructions
      Up